Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2017

Open Access 01-12-2017 | Research

Geraniin extracted from the rind of Nephelium lappaceum binds to dengue virus type-2 envelope protein and inhibits early stage of virus replication

Authors: Siti Aisyah Abdul Ahmad, Uma D. Palanisamy, Bimo A. Tejo, Miaw Fang Chew, Hong Wai Tham, Sharifah Syed Hassan

Published in: Virology Journal | Issue 1/2017

Login to get access

Abstract

Background

The rapid rise and spread in dengue cases, together with the unavailability of safe vaccines and effective antiviral drugs, warrant the need to discover and develop novel anti-dengue treatments. In this study the antiviral activity of geraniin, extracted from the rind of Nephelium lappaceum, against dengue virus type-2 (DENV-2) was investigated.

Methods

Geraniin was prepared from Nephelium lappaceum rind by reverse phase C-18 column chromatography. Cytotoxicity of geraniin towards Vero cells was evaluated using MTT assay while IC50 value was determined by plaque reduction assay. The mode-of-action of geraniin was characterized using the virucidal, attachment, penetration and the time-of-addition assays’. Docking experiments with geraniin molecule and the DENV envelope (E) protein was also performed. Finally, recombinant E Domain III (rE-DIII) protein was produced to physiologically test the binding of geraniin to DENV-2 E-DIII protein, through ELISA competitive binding assay.

Results

Cytotoxicity assay confirmed that geraniin was not toxic to Vero cells, even at the highest concentration tested. The compound exhibited DENV-2 plaque formation inhibition, with an IC50 of 1.75 μM. We further revealed that geraniin reduced viral infectivity and inhibited DENV-2 from attaching to the cells but had little effect on its penetration. Geraniin was observed to be most effective when added at the early stage of DENV-2 infection. Docking experiments showed that geraniin binds to DENV E protein, specifically at the DIII region, while the ELISA competitive binding assay confirmed geraniin’s interaction with rE-DIII with high affinity.

Conclusions

Geraniin from the rind of Nephelium lappaceum has antiviral activity against DENV-2. It is postulated that the compound inhibits viral attachment by binding to the E-DIII protein and interferes with the initial cell-virus interaction. Our results demonstrate that geraniin has the potential to be developed into an effective antiviral treatment, particularly for early phase dengue viral infection.
Literature
1.
2.
Gubler, D.J., Dengue Viruses, in Encyclopedia of Virology (Third Edition), B.W.J. Mahy and M.H.V.V. Regenmortel, Editors. 2008, Academic Press: Oxford. p. 5–14.
3.
4.
Hung S-L, et al. Analysis of the steps involved in dengue virus entry into host cells. Virology. 1999;257(1):156–67.CrossRefPubMed
5.
6.
Ocazionez RE, et al. Virucidal activity of Colombian Lippia essential oils on dengue virus replication in vitro. Mem Inst Oswaldo Cruz. 2010;105:304–9.CrossRefPubMed
7.
Patkar, C.G. and R.J. Kuhn, Development of novel antivirals against Flaviviruses, in New Treatment Strategies for Dengue and Other Flaviviral Diseases. 2008, John Wiley & Sons, Ltd. p. 41–56.
8.
9.
10.
Kaptein SJF, Neyts J. Towards antiviral therapies for treating dengue virus infections. Curr Opin Pharmacol. 2016;30:1–7.CrossRefPubMed
11.
Parida MM, et al. Inhibitory potential of neem (Azadirachta Indica Juss) leaves on dengue virus type-2 replication. J Ethnopharmacol. 2002;79(2):273–8.CrossRefPubMed
12.
Lee S, et al. Effects of cocktail of four local Malaysian medicinal plants (Phyllanthus spp.) against dengue virus 2. BMC Complement Altern Med. 2013;13(1):192.CrossRefPubMedPubMedCentral
13.
Jassim SAA, Naji MA. Novel antiviral agents: a medicinal plant perspective. J Appl Microbiol. 2003;95(3):412–27.CrossRefPubMed
14.
Ong PK, Acree TE, Lavin EH. Characterization of volatiles in Rambutan fruit (Nephelium Lappaceum L.). J Agric Food Chem. 1998;46(2):611–5.CrossRefPubMed
15.
Palanisamy UD, et al. Rapid isolation of geraniin from Nephelium Lappaceum rind waste and its anti-hyperglycemic activity. Food Chem. 2011;127(1):21–7.CrossRef
16.
Ito H. Metabolites of the ellagitannin geraniin and their antioxidant activities. Planta Med. 2011;77(11):1110–5.CrossRefPubMed
17.
Lipińska, L., E. Klewicka, and M. Sójka, The structure, occurrence and biological activity of ellagitannins: a general review. Acta Sci. Pol., Technol. Aliment, 2014. 13(3): p. 289–299.
18.
Yang CM, et al. The in vitro activity of geraniin and 1,3,4,6-tetra-O-galloyl-beta-D-glucose isolated from Phyllanthus Urinaria against herpes simplex virus type 1 and type 2 infection. J Ethnopharmacol. 2007;110(3):555–8.CrossRefPubMed
19.
Notka F, Meier GR, Wagner R. Inhibition of wild-type human immunodeficiency virus and reverse transcriptase inhibitor-resistant variants by Phyllanthus Amarus. Antivir Res. 2003;58(2):175–86.CrossRefPubMed
20.
Li J, et al. In vitro and in vivo anti-hepatitis B virus activities of a plant extract from Geranium Carolinianum L. Antivir Res. 2008;79(2):114–20.CrossRefPubMed
21.
Yang Y, et al. Antiviral effect of geraniin on human enterovirus 71 in vitro and in vivo. Bioorg Med Chem Lett. 2012;22(6):2209–11.CrossRefPubMed
22.
23.
Perry ST, Buck MD, Shresta S. Better late than never: antivirals for dengue. Expert Rev Anti-Infect Ther. 2011;9(7):755–7.CrossRefPubMed
24.
25.
Perera A, et al. Large scale purification of geraniin from Nephelium Lappaceum rind waste using reverse-phase chromatography. Sep Purif Technol. 2012;98(0):145–9.CrossRef
26.
27.
Meneses R, et al. Inhibitory effect of essential oils obtained from plants grown in Colombia on yellow fever virus replication in vitro. Ann Clin Microbiol Antimicrob. 2009;8:8.CrossRefPubMedPubMedCentral
28.
Cheng HY, Lin CC, Lin TC. Antiherpes simplex virus type 2 activity of casuarinin from the bark of Terminalia Arjuna Linn. Antivir Res. 2002;55(3):447–55.CrossRefPubMed
29.
Daelemans D, et al. A time-of-drug addition approach to target identification of antiviral compounds. Nat Protoc. 2011;6(6):925–33.CrossRefPubMed
30.
31.
Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem. 2010;31(2):455–61.PubMedPubMedCentral
32.
Davenport A, Russell F. Radioligand binding assays: theory and practice. In: Mather S, editor. Current Directions in Radiopharmaceutical Research and Development. Netherlands: Springer; 1996. p. 169–79.CrossRef
33.
Okuda T, Yoshida T, Nayeshiro H. Geraniin, a new ellagitannin from Geranium Thunbergii. Tetrahedron Lett. 1976;17:3721–2.CrossRef
34.
Cheng HS, Ton SH, Abdul Kadir K. Ellagitannin geraniin: a review of the natural sources, biosynthesis, pharmacokinetics and biological effects. Phytochem Rev. 2016:1–35.
35.
Vaughn DW, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis. 2000;181(1):2–9.CrossRefPubMed
36.
Chee H-Y, AbuBakar S. Phylogenetic investigation of dengue virus type 2 isolated in Malaysia. Dengue Bulletin. 2003;27:100–7.
37.
Shors, T., Virus replication cycles, in Understanding viruses (Second edition). 2013, Jones & Bartlett learning: Burlington, MA. p. 46–69.
38.
Galabov, A.S., Virucidal agents in the eve of manorapid synergy. GMS Krankenhhyg Interdiszip, 2007. 2(1): p. Doc18.
39.
Perera A, Ton SH, Palanisamy UD. Perspectives on geraniin, a multifunctional natural bioactive compound. Trends Food Sci Technol. 2015;44(2):243–57.CrossRef
40.
Seema and S.K. Jain, Molecular mechanism of pathogenesis of dengue virus: Entry and fusion with target cell. Indian J Clin Biochem, 2005. 20(2): p. 92–103.
41.
Weaver JL, et al. Prevention of binding of rgp120 by anti-HIV active tannins. Biochem Pharmacol. 1992;43(11):2479–80.CrossRefPubMed
42.
Low JS, et al. Narasin, a novel antiviral compound that blocks dengue virus protein expression. Antivir Ther. 2011;16(8):1203–18.CrossRefPubMed
43.
van der Schaar HM, et al. Characterization of the early events in dengue virus cell entry by biochemical assays and single-virus tracking. J Virol. 2007;81(21):12019–28.CrossRefPubMedPubMedCentral
44.
Acosta EG, Talarico LB, Damonte EB. Cell entry of dengue virus. Futur Virol. 2008;3(5):471–9.CrossRef
45.
Bielefeldt-Ohmann H, et al. Dengue virus binding to human leukocyte cell lines: receptor usage differs between cell types and virus strains. Virus Res. 2001;73(1):81–9.CrossRefPubMed
46.
47.
48.
Chen Y, Maguire T, Marks RM. Demonstration of binding of dengue virus envelope protein to target cells. J Virol. 1996;70(12):8765–72.PubMedPubMedCentral
49.
Mairiang D, et al. Identification of new protein interactions between dengue fever virus and its hosts, human and mosquito. PLoS One. 2013;8(1):e53535.CrossRefPubMedPubMedCentral
50.
Chin JF, Chu JJ, Ng ML. The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry. Microbes Infect. 2007;9(1):1–6.CrossRefPubMed
Metadata
Title
Geraniin extracted from the rind of Nephelium lappaceum binds to dengue virus type-2 envelope protein and inhibits early stage of virus replication
Authors
Siti Aisyah Abdul Ahmad
Uma D. Palanisamy
Bimo A. Tejo
Miaw Fang Chew
Hong Wai Tham
Sharifah Syed Hassan
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2017
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-017-0895-1

Other articles of this Issue 1/2017

Virology Journal 1/2017 Go to the issue

Case report

Isolation and genetic characterization of a novel 2.2.1.2a H5N1 virus from a vaccinated meat-turkeys flock in Egypt

Research

Marburg virus-like particles by co-expression of glycoprotein and matrix protein in insect cells induces immune responses in mice

Research

Chronic hepatitis B carriers with acute on chronic liver failure show increased HBV surface gene mutations, including immune escape variants

Research

Rubella, herpes simplex virus type 2 and preeclampsia

Research

The dose of HBV genome contained plasmid has a great impact on HBV persistence in hydrodynamic injection mouse model

Review

Mucus and Mucins: do they have a role in the inhibition of the human immunodeficiency virus?

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits